ArticleDiscover oncology2025
Multi-omics analysis reveals cancer stemness function and establishes a predictive model for thyroid cancer prognosis and immunotherapy.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer stem cells (CSCs) play a crucial role in the progression of tumors, resistance to immunotherapy, and the development of thyroid carcinoma (THCA). However, the precise mechanisms involved remain poorly understood. In this study, 26 mRNAs linked to cancer stemness were identified through an analysis of 13 publicly available THCA transcriptomic datasets alongside a CRISPR dataset for thyroid cancer cell lines. Notably, we revealed an inverse relationship between the stemness of cancer cells and the efficacy of immunotherapy. Utilizing multiple machine learning approaches, we created and confirmed a model for tumor stemness cells (TSC), which included genes associated with cancer stemness. This model successfully forecasted patient outcomes and responses to treatment with Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4) immune checkpoint inhibitors (ICIs) across different types of cancer. Additionally, chromosomal amplifications in regions 1q and 8p were identified as intrinsic contributors to the onset of thyroid cancer. Specifically, based on single cell dataset, the amplification of CKS1B on chromosome 1q was revealed to advance the progression of thyroid cancer cells by boosting their proliferation. Furthermore, experimental results revealed that the heightened expression of CKS1B considerably enhanced the proliferation and invasion capabilities of THCA, suggesting it could serve as a possible therapeutic target for this condition. In summary, our study sheds light on the relationship between the traits of cancer stem cells and the efficacy of immunotherapy, providing a novel model for predicting the prognosis and individual responses to immunotherapy in patients with THCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.